Marcaine Post-Operative Pain Study

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04494880

Enrollment

Registered

2020-07-31

Start date

2020-12-09

Completion date

2022-12-31

Last updated

2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of Drug

Brief summary

The study examines the efficacy of Marcaine in post-operative pain reduction for patients receiving breast reduction surgery. Patients who consent will be randomized to which breast receives a Marcaine injection and the other breast will have saline injected. Pain will be assessed one time post-operatively using a 1-10 pain scale.

Interventions

DRUGBupivacaine Injection

Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

No minimum to 89 Years

Healthy volunteers

Yes

Inclusion criteria

* Must be receiving bilateral breast reduction surgery

Exclusion criteria

* Unilateral breast reduction surgery

Design outcomes

Primary

Measure	Time frame	Description
Marcaine Use in Breast Reconstruction: Post-Operative Pain Scale Assessment per Breast	through study completion, an average of 1 year	Minimum score: 1 (minimal pain), Maximum score: 10 (worst pain possible/worst outcome), higher pain scores associated with worse outcomes

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026